Cecily Palmer

Cecily Palmer

Auto-generated profile, based on publicly available information

Cecily Palmer

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CPCecily K. Palmer
Cecily K. Palmer
RGRachael Gooberman-Hill
Rachael Gooberman-Hill
ABAshley W. Blom
Ashley W. Blom
MWMichael Whitehouse
Michael Whitehouse
AMAndrew J. Moore
Andrew J. Moore
Deep prosthetic hip infection is a devastating complication of hip replacement surgery, and treatment often involves multiple revision surgeries with antibiotic chemotherapy to control the infection. The aim of this study was to explore patients’ experiences of early and longer-term recovery after one-stage or two-stage revision with an excised hip, a temporary cement spacer or a custom-made articulating spacer. We interviewed 32 participants taking part in a surgical trial at two time points (2–4 months and 18 months) following one- or two-stage revision surgery. The analytic approach was inductive using the constant comparative method to generate themes from the data. Participants’ early recovery after revision was characterised by a long hospital stay with burdensome antibiotics and limited physiotherapy provision. Participants undergoing two-stage revision with an excised hip or a cement spacer described severe mobility restrictions which affected all aspects of their lives, while those undergoing one-stage revision, or two-stage revision with an articulating spacer were more mobile and independent, with some limitations. Participants with a cement spacer also reported more pain than other treatment groups, while those with an articulating spacer appeared to perceive that their recovery was slow. At 18 months, participants in all groups described both improvements and losses in mobility and functional ability. Participants in all treatment groups expressed considerable emotional resilience during recovery from revision, which may be linked to opportunities to talk with the trial personnel. Participants identified the need for better information and psychological and physical support. Experience of recovery differs after one- and two-stage revision, and further in relation to the use of spacers. Mobility, function, independence and pain are important aspects of recovery which affect all aspects of day-to-day life. Increased information and more opportunities to talk and share experiences may provide psychological support during recovery.

1 November 2022 in Programme Grants for Applied Research
Verified
Journal Article
Open access
PDF file
ABAshley W Blom
Ashley W Blom
ABAndrew D Beswick
Andrew D Beswick
ABAmanda Burston
Amanda Burston
FCFran E Carroll
Fran E Carroll
KGKirsty Garfield
Kirsty Garfield
MWMichael Whitehouse
Michael Whitehouse
Background: People with severe osteoarthritis, other joint conditions or injury may have joint replacement to reduce pain and disability. In the UK in 2019, over 200,000 hip and knee replacements were performed. About 1 in 100 replacements becomes infected, and most people with infected replacements require further surgery. Objectives: To investigate why some patients are predisposed to joint infections and how this affects patients and the NHS, and to evaluate treatments. Design: Systematic reviews, joint registry analyses, qualitative interviews, a randomised controlled trial, health economic analyses and a discrete choice questionnaire. Setting: Our studies are relevant to the NHS, to the Swedish health system and internationally. Participants: People with prosthetic joint infection after hip or knee replacement and surgeons. Interventions: Revision of hip prosthetic joint infection with a single- or two-stage procedure. Main outcome measures: Long-term patient-reported outcomes and reinfection. Cost-effectiveness of revision strategies over 18 months from two perspectives: health-care provider and Personal Social Services, and societal. Data sources: National Joint Registry; literature databases; published cohort studies; interviews with 67 patients and 35 surgeons; a patient discrete choice questionnaire; and the INFORM (INFection ORthopaedic Management) randomised trial. Review methods: Systematic reviews of studies reporting risk factors, diagnosis, treatment outcomes and cost comparisons. Individual patient data meta-analysis. Results: In registry analyses, about 0.62% and 0.75% of patients with hip and knee replacement, respectively, had joint infection requiring surgery. Rates were four times greater after aseptic revision. The costs of inpatient and day-case admissions in people with hip prosthetic joint infection were about five times higher than those in people with no infection, an additional cost of > £30,000. People described devastating effects of hip and knee prosthetic joint infection and treatment. In the treatment of hip prosthetic joint infection, a two-stage procedure with or without a cement spacer had a greater negative impact on patient well-being than a single- or two-stage procedure with a custom-made articulating spacer. Surgeons described the significant emotional impact of hip and knee prosthetic joint infection and the importance of a supportive multidisciplinary team. In systematic reviews and registry analyses, the risk factors for hip and knee prosthetic joint infection included male sex, diagnoses other than osteoarthritis, high body mass index, poor physical status, diabetes, dementia and liver disease. Evidence linking health-care setting and surgeon experience with prosthetic joint infection was inconsistent. Uncemented fixation, posterior approach and ceramic bearings were associated with lower infection risk after hip replacement. In our systematic review, synovial fluid alpha-defensin and leucocyte esterase showed high diagnostic accuracy for prosthetic joint infection. Systematic reviews and individual patient data meta-analysis showed similar reinfection outcomes in patients with hip or knee prosthetic joint infection treated with single- and two-stage revision. In registry analysis, there was a higher rate of early rerevision after single-stage revision for hip prosthetic joint infection, but, overall, 40% fewer operations are required as part of a single-stage procedure than as part of a two-stage procedure. The treatment of hip or knee prosthetic joint infection with early debridement and implant retention may be effective in > 60% of cases. In the INFORM randomised controlled trial, 140 patients with hip prosthetic joint infection were randomised to single- or two-stage revision. Eighteen months after randomisation, pain, function and stiffness were similar between the randomised groups (p = 0.98), and there were no differences in reinfection rates. Patient outcomes improved earlier in the single-stage than in the two-stage group. Participants randomised to a single-stage procedure had lower costs (mean difference –£10,055, 95% confidence interval –£19,568 to –£542) and higher quality-adjusted life-years (mean difference 0.06, 95% confidence interval –0.07 to 0.18) than those randomised to a two-stage procedure. Single-stage was the more cost-effective option, with an incremental net monetary benefit at a threshold of £20,000 per quality-adjusted life-year of £11,167 (95% confidence interval £638 to £21,696). In a discrete choice questionnaire completed by 57 patients 18 months after surgery to treat hip prosthetic joint infection, the most valued characteristics in decisions about revision were the ability to engage in valued activities and a quick return to normal activity. Limitations: Some research was specific to people with hip prosthetic joint infection. Study populations in meta-analyses and registry analyses may have been selected for joint replacement and specific treatments. The INFORM trial was not powered to study reinfection and was limited to 18 months’ follow-up. The qualitative study subgroups were small. Conclusions: We identified risk factors, diagnostic biomarkers, effective treatments and patient preferences for the treatment of hip and knee prosthetic joint infection. The risk factors include male sex, diagnoses other than osteoarthritis, specific comorbidities and surgical factors. Synovial fluid alpha-defensin and leucocyte esterase showed high diagnostic accuracy. Infection is devastating for patients and surgeons, both of whom describe the need for support during treatment. Debridement and implant retention is effective, particularly if performed early. For infected hip replacements, single- and two-stage revision appear equally efficacious, but single-stage has better early results, is cost-effective at 18-month follow-up and is increasingly used. Patients prefer treatments that allow full functional return within 3–9 months. Future work: For people with infection, develop information, counselling, peer support and care pathways. Develop supportive care and information for patients and health-care professionals to enable the early recognition of infections. Compare alternative and new treatment strategies in hip and knee prosthetic joint infection. Assess diagnostic methods and establish NHS diagnostic criteria. Study registration: The INFORM randomised controlled trial is registered as ISRCTN10956306. All systematic reviews were registered in PROSPERO (as CRD42017069526, CRD42015023485, CRD42018106503, CRD42018114592, CRD42015023704, CRD42017057513, CRD42015016559, CRD42015017327 and CRD42015016664). Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research; Vol. 10, No. 10. See the NIHR Journals Library website for further project information.

1 November 2025 in Health Technology Assessment
Verified
Journal Article
Open access
MWMichael Whitehouse
Michael Whitehouse
AJAndrew Judge
Andrew Judge
SHSamuel Hawley
Samuel Hawley
AUAlbert Prats Uribe
Albert Prats Uribe
ADAntonella Delmestri
Antonella Delmestri
DPDaniel Prieto-Alhambra
Daniel Prieto-Alhambra
Background: Intra-articular corticosteroid injections are an adjunct to core treatments for osteoarthritis. The National Institute for Health and Care Research Health Technology Assessment programme commissioned this research to address uncertainty around the long-term benefits and potential risks associated with recurrent intra-articular corticosteroid injections. Objectives: Characterise current intra-articular corticosteroid injection practice. Establish longer-term effects and safety of single and recurrent intra-articular corticosteroid injections. Explore views and experiences of patients and clinicians. Assess the priorities/feasibility for future research. Methods: A cohort study of incident osteoarthritis patients (2005–20) was performed using United Kingdom primary care data (Clinical Practice Research Datalink) linked to hospital data (Hospital Episode Statistics). Incidence of first intra-articular corticosteroid injection was stratified by age, calendar year, gender and geographical region. Longer-term outcomes included incident pain medication and joint replacement. Instrumental variables based on practice preference for intra-articular corticosteroid injection were used in primary analyses. Safety was assessed with propensity score matching and a self-controlled cohort, with outcomes (mortality, bleeding, hemarthrosis, wound infection, diabetes, stroke, ischaemic heart disease, myocardial infarction) assessed at 6 months. Semistructured telephone/videocall interviews were conducted (patients = 38, primary care clinicians = 19), with inductive thematic analysis used to investigate views and experiences of intra-articular corticosteroid injections. A three-round modified Delphi study with patients ( n = 41), healthcare professionals ( n = 25) and academics/researchers ( n = 25) was performed to identify future primary research priorities and feasibility. Results: There were 23,899 (10.8%) osteoarthritis patients receiving intra-articular corticosteroid injections (40% received > 1 injection). Incidence of intra-articular corticosteroid injection at 5-year follow-up was lowest for elbow (5.2%) and highest for shoulder (13.6%). Incidences remained stable for all joints between 2005 and 2019 but varied between regions {3.8 [95% confidence interval 3.4 to 4.1] to 1.4 [95% confidence interval 1.3 to 1.5] injections per 100 patient-years}. Intra-articular corticosteroid injection for knee osteoarthritis was associated with lower incident use of several pain medications at 5-year follow-up; recurrent knee intra-articular corticosteroid injections were associated with greater risk reduction. In primary analyses intra-articular corticosteroid injection was associated with a lower 5-year cumulative incidence of knee replacement (number needed to treat 17, 95% confidence interval 12 to 40), but not hip replacement. In certain analyses, incidences of diabetes, ischaemic heart disease and myocardial infarction were numerically higher with intra-articular corticosteroid injections but 95% confidence interval spanned the null; there were no significant associations with other outcomes. Qualitative interviews demonstrated clinicians were more cautious about administering intra-articular corticosteroid injections compared to patients considering receiving intra-articular corticosteroid injections. Patients valued intra-articular corticosteroid injections; however, access was variable, with contributory factors including clinician concerns about the evidence base and their individual competence and confidence performing intra-articular corticosteroid injections. The Delphi research priority list included 14 questions covering long-term effects, clinical and cost-effectiveness, outcomes measurement, comparison to other treatments, provision, safety, identifying responders, maximising benefits, patient experience, delaying joint replacement and dosage. Limitations: Observational analyses: Possibility of residual confounding. Qualitative research: Self-selecting nature of participation; and while the funding remit focussed on primary care, qualitative findings suggest orthopaedic consultants are key stakeholders. Delphi study: Unable to engage commissioners. Conclusions: Overall, in the UK, intra-articular corticosteroid injection use is unchanged over 15 years; however, there was wide regional heterogeneity. We observed a sustained reduction in usage of certain pain medications after intra-articular corticosteroid injections. Intra-articular corticosteroid injections appear generally safe, although more research is needed on potential safety signals, particularly diabetes and cardiovascular events. Future work: A Delphi study with key stakeholders identified 14 priority questions to guide future intra-articular corticosteroid injection research. Work exploring regional variation in intra-articular corticosteroid injection access would be beneficial. Study registration: This study is registered as ISRCTN32433800; Independent Scientific Advisory Committee (ISAC) for the Medicines and Healthcare Products Regulatory Agency (ISAC protocol no. 20_067RA). Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR129011) and is published in full in Health Technology Assessment ; Vol. 29, No. 56. See the NIHR Funding and Awards website for further award information.

1 May 2026 in The Bone & Joint Journal
Verified
Journal Article
Open access
PDF file
Petra BajiPetra Baji
Petra Baji
CPCecily Palmer
Cecily Palmer
AMAndrew J. Moore
Andrew J. Moore
MWMichael Whitehouse
Michael Whitehouse
JEJonathan T. Evans
Jonathan T. Evans
EMElsa M. R. Marques
Elsa M. R. Marques
Aims: The aim of this study was to report the findings of a national survey of consultant hip surgeons in the UK investigating their practice and factors which influence their choice of the method of fixation when undertaking primary elective total hip arthroplasty (THA). Methods: An online survey was conducted in 2024 with questions about surgeons’ practice, a rating exercise with open text questions, and a discrete choice experiment (DCE). In the DCE, surgeons were presented with ten randomly assigned profiles of patients described by age, sex, level of activity, risk of medical problems, and risk of fracture, and were asked to choose their preferred method of fixation (cemented, uncemented, or hybrid) for each. Results: A total of 101 consultants performing a mean 121 (SD 81) primary elective THAs annually for a mean 12.5 years (SD 8.5) completed the survey. For patients aged < 70 years, 61 (60%) would use hybrid, 31 (31%) uncemented, and nine (9%) cemented THAs. For patients aged > 70 years, 56 (55%) would use hybrid, 33 (33%) cemented, 11 (11%) uncemented, and one (1%) a reverse hybrid. In the DCE, the most influential characteristics of a patient were their age and level of activity. For a ‘moderately active’ male patient, the probability of surgeons choosing a cemented THA was 10% at the age of 65 years and 39% at the age of 85 years. These probabilities were 15% and 47% for a female patient. An increased perceived risk of fracture decreased the probability of choosing an uncemented THA. A total of 24 surgeons chose the same implant regardless of the patient’s profile. In the rating exercise, the most influential factors besides the characteristics of the patient were the revision rate, the personal audit of the surgeon’s practice, and the published evidence and guidelines. Analysis of free-text responses identified further important influencing factors such as the patient’s anatomy and bone quality, and the surgeons’ training, skill, and experience. Conclusion: This is the largest survey of UK consultant hip surgeons providing an understanding of the determinants of choices of the type of THA when undertaking primary THA in patients with hip osteoarthritis. These findings will inform the implementation of the findings of studies involving THA in relation to the practices of surgeons in the ‘real world’. Cite this article: Bone Joint J 2026;108-B(5):597–606.

10 July 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
CPCecily Palmer
Cecily Palmer
Petra BajiPetra Baji
Petra Baji
MWMichael Whitehouse
Michael Whitehouse
JEJonathan Thomas Evans
Jonathan Thomas Evans
ABAshley W Blom
Ashley W Blom
AMAndrew J Moore
Andrew J Moore
Objectives: To explore the views of UK-based consultant hip surgeons about implant fixation choice and identify factors that inform decision-making about use of cemented, hybrid or uncemented implant fixation when performing total hip replacement in adults aged under 70 years. Design: Qualitative semistructured interview study. Recruitment was through consultant participation in a national online survey. Purposive sampling was used to ensure a range of implant fixation methods in the final sample. Data were audio recorded, transcribed, anonymised and analysed inductively to generate themes describing influential factors on surgeons’ decision-making about fixation choice. Setting: UK elective primary total hip arthroplasty. Consultant hip surgeons representing 15 English NHS sites and 2 Scottish Health Boards and one private surgeon took part in a telephone or online interview. Participants: 20 consultant hip surgeons participated, with consultant-level years in practice ranging from 1 to 25+ years. Seven participants primarily used cemented/hybrid constructs and 13 primarily used uncemented/hybrid constructs in patients aged under 70. Results: Six themes describing influences on surgeons’ decision-making about fixation were identified; ‘patient characteristics’; ‘patient preferences and implant availability’; ‘training and establishing a fixation skillset’; ‘formal evidence of outcomes’, ‘personal outcomes and accumulated clinical experience’ and ‘surgical speed and cost effectiveness as secondary benefits’. All surgeons described patient characteristics that influenced their decision-making, and the sample contained surgeons who preferred cemented, hybrid and uncemented constructs respectively for young, uncomplicated patients. Bone quality was particularly influential and surgeons used age, comorbidities, activity level and sex as indicators of likely bone quality. Poorer bone was agreed to require a cemented stem; however, cup fixation varied, resulting in use of cemented and hybrid constructs when bone was poor. Varied femoral anatomy, including Dorr C, was commonly deemed to require cemented stems within either cemented or hybrid constructs; dysplastic or sclerotic sockets were deemed to require uncemented cups within either uncemented or hybrid constructs. Patient characteristics such as body mass index, likely need for future revision and risk of infection were influential, but not towards any single fixation method. Many surgeons described being trained into geographical/unit fixation traditions, building skill in two fixation methods rather than three. Good outcomes were undetachable from skilled expertise and therefore continued use of specific fixations was reinforced, particularly when surgeons’ personal National Joint Registry outcomes evidenced good performance. Regardless of fixation method preferences, surgeons referred to (at times the same) formal research evidence that supported their fixation choices, as well as their accumulated clinical experience. Increased surgical speed of uncemented components and lower implant cost were not perceived to be key drivers of fixation choice as patient outcomes were prioritised. However, surgical speed was acknowledged as potentially influential in relation to private practice or high volume lists, and costs considered secondarily if good implant outcomes had been established by formal evidence. Conclusions: Multiple factors exert influence on surgeons’ decision-making about fixation. Community equipoise was identified among UK hip surgeons relating to which fixation method is superior for young, uncomplicated patients or relative to patient characteristics. Trial registration number: ISRCTN14346605 .

16 May 2026 in British Journal of Pain
Verified
Journal Article
Open access
CPCecily K. Palmer
Cecily K. Palmer
VWVikki Wylde
Vikki Wylde
CPCathy Price
Cathy Price
KAKate E. Ashton
Kate E. Ashton
AMAndrew J. Moore
Andrew J. Moore
Aims: A qualitative process evaluation was embedded into the pilot phase of the RADICAL randomised controlled trial of radiofrequency denervation for chronic and moderate-severe low back pain. The aim was to rapidly understand recruitment processes and inform development of strategies to overcome recruitment challenges. Methods: Audio recording of recruitment consultations between recruiting staff and potential patient participants, and interviews with patients who had consented to participate in the RADICAL trial. We used rapid thematic analysis to identify what information was provided, understanding of trial processes and potential challenges to recruitment. Results: Recruitment staff needed more support to clearly and effectively explain trial participation. Specific challenges included communicating trial procedures, explaining treatment equipoise and randomisation, and navigating the complex recruitment pathway. These findings led to the development of support materials for recruiters, including a process diagram and targeted training sessions to optimise information provision and informed consent. Conclusion: Embedding qualitative process evaluations within an RCT pilot can generate rapid insights into communication challenges and recruitment barriers. These insights can inform the development of practical support materials and process refinements to enhance recruitment, potentially strengthening trial viability.